Treatment-Related Adverse Events

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Presented at ESMO with a concurrent NEJM publication, the phase 3 data indicate a potential new first-line option for patients ineligible for immunotherapy pending mature survival results.